K2 Therapeutics
Singapore’s biotechnology firm K2 Therapeutics raises $50M in seed financing from MPM BioImpact
K2 Therapeutics, a Singapore-based biotechnology company, has raised $50 million in seed financing from MPM BioImpact, the U.S. investment firm that founded the company in 2024.
